statement
In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.
A statement by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.
D2T RA 2b상 Period 2 결과에서 600mg 지속 투약군이 통계적 유효성(p-value)을 달성하며 시장 기대를 뛰어넘는 서프라이즈 기록
Discussion
Related claims
In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved a p-value.하나증권 제약/바이오 김선아 · statementThe 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementFrom year-end, the D2T RA approval direction will be discussed with the FDA, and GD (Phase 2b) and MG (Phase 3) top-line results are scheduled for 2027.하나증권 제약/바이오 김선아 · commitmentFollowing the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.report author · statementImmunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.report author · statementIMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.report author · statement